Exelixis found using ticker (EXEL) now have 13 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 35 and 20 calculating the mean target price we have 24.54. Given that the stocks previous close was at 16.77 this is indicating there is a potential upside of 46.3%. The day 50 moving average is 18.85 and the 200 day MA is 18.01. The market capitalisation for the company is $4,958m. Find out more information at: http://www.exelixis.com
Exelixis, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company’s products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. Exelixis has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Invenra, StemSynergy Therapeutics, Genentech, GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals and changed its name to Exelixis in February 2000. Exelixis was founded in 1994 and is headquartered in Alameda, California.